# Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer

> **NCT06599775** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Resectable Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Adebrelimab injection
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Carboplatin injection

## Key facts

- **NCT ID:** NCT06599775
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06599775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06599775, "Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06599775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*